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Abstract 
Objective: This study was designed to evaluate the association of serum levels of 
angiopoietin-like protein 2 (ANGPTL2) with circulating inflammatory markers and 
oxidized and modified low density lipoprotein cholesterol (LDL) evaluated by lectin-
like oxidized LDL receptor 1 containing apolipoprotein B (LAB) in type 2 diabetic 
patients. 
Methods: The study included 70 type 2 diabetic patients hospitalized for glycemic 
control and 9 control subjects. 
Results: The serum levels of ANGPTL2 were significantly elevated in the type 2 
diabetic patients compared with that in the healthy controls. There was a significant 
positive correlation between ANGPTL2 and either high sensitivity C reactive protein, 
fibrinogen, or LAB levels, and a significant negative correlation between ANGPTL2 
and estimated glomerular filtration rate (eGFR) levels.  
Conclusions: The results suggest that serum ANGPTL2 levels have a close positive 
association with inflammatory markers, especially fibrinogen and oxidized and 
modified LDL as evaluated by LAB, and that serum ANGPTL2 levels are influenced by 
renal function as reflected by the eGFR. 
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Introduction 
Angiopoietin-like proteins (ANGPTLs) are glycosylated proteins with an N-terminal 
coiled domain and a C-terminal fibrinogen-like domain except for ANGPTL8. These are 
structurally similar to angiopoietins. Currently 8 members (ANGPTL1-8) of this family 
have been identified.1-3. Although ANGPTLs cannot bind to the angiopoietin receptors, 
such as Tie2 or to the related protein Tie11,2, they can regulate angiogenesis similar to 
that by the angiopoietins.2,3 In addition, some of the ANGPTLs, including ANGPTL3, 4, 
6, and 8, also contribute to lipid, glucose, and/or energy metabolisms.1-7 
ANGPTL2 is abundantly expressed in visceral adipose tissues.2,3,8 Apart from its 
angiogenic activity, it causes inflammation of adipose-tissue in obesity resulting in 
insulin resistance in humans.2,3,8 Furthermore, ANGPTL2 can also cause vascular 
inflammation,8 endothelial dysfunction,9 and increased oxidative stress10, and it may be 
associated with tumor metastasis.11 Although the main sources of circulating ANGPTL2 
in humans appear to be adipocytes, endothelial cells, and infiltrated macrophages in 
visceral fat tissues,2,3 it can also be secreted by the heart,1,12 and by both endothelial 
cells13 and macrophages14 in various other tissues. Interestingly, recent reports 
demonstrated that circulating ANGPTL2 levels are associated with the new onset of 
type 2 diabetes,15 and with both cardiovascular events and mortality in type 2 diabetic 
patients.16 In type 2 diabetic patients, the association of circulating ANGPTL2 levels 
with high sensitivity C reactive protein (hsCRP) as a circulating inflammation-marker 
has been previously reported.8,17 However, the association between ANGPTL2 levels 
with other inflammatory markers, such as fibrinogen, has not yet been investigated. The 
association between ANGPTL2 and fibrinogen levels may be particularly interesting 
because ANGPTLs, including ANGPTL2, have a fibrinogen-like domain at the C 
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terminus as described above.1-3 Furthermore, although it is evident that low density 
lipoprotein cholesterol (LDL-C) is the most important established marker for 
cardiovascular risk in type 2 diabetes (18), recently the importance of oxidation of LDL 
for the progression of atherosclerosis has been recognized19. Oxidized LDL, but not 
LDL, binds to the lectin-like oxidized LDL receptor 1 (LOX-1, an oxidized and 
modified LDL receptor) in vascular endothelial cells20 and can play an important role in 
the formation of an atheroma.19 LOX-1 ligands containing apolipoprotein B (LAB)21 are 
a marker of the atherogenicity of oxidized and modified LDL more specifically than one 
antigenic determinant of oxidized LDL.22, 23 Since ANGPTL2 can enhance both 
inflammation and oxidative stress,8,10 we hypothesized that there was a potential 
relationship between ANGPTL2 and LAB. 
We investigated the association between circulating ANGPTL2 levels and 
inflammatory markers, such as hsCRP and fibrinogen, circulating soluble (s) LOX-1, 
and circulating LAB in type 2 diabetic patients. We also evaluated the association of 
ANGPTL2 with the various markers related to type 2 diabetes. We hypothesized that 
circulating ANGPTL2 levels would be positively associated with hsCRP and fibrinogen, 
and that these would also be positively associated with LAB levels rather than with 
sLOX-1 levels. 
 
Methods 
Patients 
This study was registered in UMIN000025767. A total of 70 hospitalized type 2 
diabetic patients were prospectively and consecutively enrolled from February 2017 and 
to August 2017. 
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The detailed key inclusion and exclusion criteria of the type 2 diabetic patients in the 
study has been previously described in the UMIN clinical registered system24. The 
characteristics of the 70 patients and 9 healthy subjects on enrollment are shown in 
Table 1. 
 
Methods 
  Blood tests on the type 2 diabetic patients were performed at 9:00 a.m. after an 
overnight fast for at least 10 hr on the day after hospitalization. The control subjects also 
had the blood tests performed under similar conditions, although they were not 
hospitalized. Until analysis, samples for analyses of ANGPTL2, LOX-1, and LAB were 
preserved frozen at -80C. At the time of sampling, measurements of body weight (BW) 
and blood pressure were also performed. 
Measurement of serum ANGPTL2 levels 
Fasting serum ANGPTL2 levels were measured in duplicate using a human 
ANGPTL2 enzyme-linked immunosorbent (ELISA) assay kit (sandwich ELISA) 
(Human ANGPTL2 assay Kit-IBL, code no. 27745, Immuno-Biological Laboratories 
Co., Ltd, Gumma, Japan). The intra-assay and inter-assay CV were 3.9-5.9% and 6.3-
10.5%, respectively25, based on the manufacturer’s information. 
Measurement of serum sLOX-1 and LAB levels 
The measurement of the plasma levels of sLOX-1 was performed using a sandwich 
chemiluminescence enzyme immunoassay (CLEIA) with two different monoclonal 
antibodies against the extracellular domain of LOX-1 (B017M and a chicken 
monoclonal anti-human LOX-1 antibody HUC3-48). The plasma levels of LAB were 
measured by a sandwich CLEIA using recombinant sLOX-1 and a monoclonal antibody 
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against the extracellular domain of ApoB (a chicken monoclonal anti-human ApoB 
antibody HUC20). 
Measurement of the intimal medial complex thickness of the carotid artery (IMT) 
The IMT was evaluated in the carotid artery on the right side using echography 
(TOSHIBA aplico i900 and aplicoXV, TOSHIBA, Tokyo, Japan). The maximum point 
in 3 suitable consecutive points with 1 cm intervals was estimated as the IMT in each 
patient. 
Measurements of fasting plasma glucose, HbA1c, and insulin levels 
Fasting plasma glucose (FPG) was measured just after blood collection using an 
automated glucose oxidase analysis system (Glucose Auto Stat GA1160; Arkray, 
Kyoto, Japan). HbA1c was evaluated by an enzymatic assay using protease in the first 
order reaction and both fructosylpeptide oxidase (FPOX) and peroxidase (POD) in the 
second order reaction (NordiaN HbA1c, Sekisui Medical Inc., Tokyo, Japan). Serum 
insulin levels (immune-reactive insulin) were evaluated by a CLEIA using the lumipulse 
Presto Insulin Kit (Fujirebio, Tokyo, Japan). 
Homeostasis model assessment-insulin resistance (HOMA-IR.) 
HOMA-IR was used as an indicator of insulin resistance and was calculated as 
follows: HOMA-IR = FPG (mg/dL) × immunoreactive insulin (μU/mL)/405.26 
Estimated glomerular filtration rate (eGFR) 
The estimated glomerular filtration rate (eGFR) was calculated as follows: for men, 
eGFR (ml/min/1.73 m2) =194×creatinine (mg/dL)-1.094×age (year)-0.287, and for women, 
eGFR (ml/min/1.73 m2) =194×creatinine (mg/dL)-1.094×age (year)-0.287 ×0.739.27  
Measurement of serum hsCRP and plasma fibrinogen 
HsCRP was measured by the latex agglutination method using a kit, CRP-LatexX2 
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Seiken (Denka Seiken Co., Ltd, Tokyo, Japan), and plasma fibrinogen was measured 
based on the thrombin time method using a fibrinogen kit Coagpia (Sekisui Medical 
Co., Ltd, Tokyo, Japan). 
Evaluation of diabetic retinopathy 
Diabetic retinopathy, including no diabetic retinopathy (NDR), simple diabetic 
retinopathy (SDR), and proliferative diabetic retinopathy (PDR), was evaluated based 
on the Davis’ criteria28) by ophthalmologists in our hospital. 
Ethical considerations. All subjects gave written informed consent for inclusion in 
this study, and the Local Ethics Committee at our hospital approved this study. This 
study was performed according to the guidelines of the Declaration of Helsinki. 
Statistical methods. We expected that a correlation coefficient is greater than 0.35 
between ANGPTL2 and other important biomarkers when these correlations are 
statistically significant. The required sample sizes would respectively be 85 and 62 
for mother correlation coefficients of 0.3 and 0.35, with 0.05 of significance levels 
(two-sides) and 0.8 of power. The normality of the data in each variable was confirmed 
by an 2 goodness of fit test and/or by a Kolmogorov-Smirnov test. Serum ANGPTL2 
levels had a normal distribution. Among the variables included in Table 2, body mass 
index (BMI), diastolic blood pressure (DBP), LDL-C, fibrinogen, and CAVI-index had 
normal distributions. Therefore, the correlation of ANGPTL2 with these variables was 
confirmed using Pearson’s correlation. The remaining variables had skewed 
distributions. Among the variables with a skewed distribution, FPG, HbA1c, TG, HDL-
C, Insulin, HOMA-R, hsCRP, eGFR, and LAB had normal distributions after log10-
transformation. Therefore, the association of ANGPTL2 with these variables was 
confirmed using the data after log10-transformation by Pearson’s correlation. All of the 
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remaining variables did not have a normal distribution even after log10-transformation. 
Thus, the correlation between ANGPTL2 and these variables was confirmed using 
Spearman’s correlation as a non-parametric coefficient. In multiple regression analysis, 
we used 2 types of model groups, i.e., an inflammatory-related group and a metabolic-
related group. Except for ANGPTL2, BMI, LDL-C, and fibrinogen, these variables 
were log10-transformed. Comparisons between type 2 diabetic patients and healthy 
subjects for BMI were performed using an unpaired t test. Comparisons between these 
groups for age, FPG, HbA1c, and eGFR were performed by the Mann-Whitney U test 
because of the skewed distribution of these variables. Comparisons for ANGPTL2 
between the two groups were performed using an unpaired t-test. For comparison of 
ANGPTL2 among the 3 groups, the homogeneity was confirmed using by the Bartlett 
test. A parametric comparison was done using one-way analysis of variance (ANOVA) 
after the confirmation of equal variance. After the confirmation of the significance by 
the ANOVA, a post hoc Holm test was conducted. All statistical analyses were 
performed using Ekuseru-Toukei 2012 software (Social Survey Research Information 
Co., Ltd, Tokyo, Japan). A P value of less than 0.05 was considered as statistical 
significance (two-sided). 
 
Results 
The serum ANGPTL2 levels were significantly elevated in type 2 diabetic patients (n 
=70) compared with that in the healthy controls (n =9) [3.47 ± 1.10 (range with 1.65-
6.91) vs. 2.51± 0.42 ng/mL (range with 1.99-3.04)] (P <0.0001) (Fig. 1A). 
There were no gender-related differences. ANGPTL2 levels for men and for women 
were respectively 3.42 ± 1.07 and 3.57 ± 1.13 ng/mL (P =0.6050). When the patients 
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were classified into 2 groups with (n =20) and without statins (n =50), the serum 
ANGPTL2 levels were respectively 3.16 ± 0.67 vs. 3.60 ± 1.21 ng/mL with a trend 
toward lower values in the ANGPTL2 levels in the group treated with statins vs. the 
group not treated with statins (P =0.0551). There were no significant differences in the 
ANGPTL2 levels in patients with (n =35) and without insulin therapy (n =35) (3.45 ± 
1.08 vs. 3.50± 1.12 ng/mL, P =0.8697). In addition, no difference was noted between 
patients having (n =29) and not having (n =41) a current smoking habit (P =0.8398). 
Furthermore, when patients were divided into 3 groups based on the degree of diabetic 
retinopathy [NDR (n =52), SDR (n =5), PDR (n =13)], the serum ANGPTL2 levels 
were 3.45 ± 1.14, 3.61 ± 1.22, and 3.51 ± 0.93 ng/mL, respectively. There were no 
significant differences in the ANGPTL2 levels among these groups [NDR vs. SDR (P 
=1.0000), NDR vs. PDR (P =1.0000), and SDR vs. PDR (P =1.0000)]. 
The data obtained from the correlation of the ANGPTL2 levels with multiple 
variables and the data obtained from the multiple regression analysis for the ANGPTL2 
levels as the dependent variable are summarized in Tables 2 and 3. A significant positive 
correlation between ANGPTL2 and hsCRP, fibrinogen, and LAB levels (P =0.0457, P 
=0.0001, and P =0.0147) and a significant negative correlation between ANGPTL2 
levels and the eGFR (P =0.0063) were found. For patients not on insulin therapy whose 
serum insulin levels were measured (n =30), there was a significant positive correlation 
between ANGPTL2 and HOMA-IR levels (P =0.0419). In multiple regression analysis, 
ANGPTL2 had a significant positive association with fibrinogen in all models (models 
2-4), including fibrinogen in the inflammatory-related model group, while ANGPTL2 
did not have a significant association with hsCRP, excluding model 1 in this model 
group. ANGPTL2 also had a significant positive association with LAB in the models, 
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including LAB (models 3 and 4) in this model group. In the metabolic-related model, 
ANGPTL2 did not have significant associations with HbA1c, BMI, TG, and LDL-C, 
excluding 1 model with HbA1c (Model 1). ANGPTL2 showed either a significant 
negative association or a trend toward a negative association with eGFR in all models in 
both the inflammatory-related and metabolic-related models. We also investigated the 
correlation between ANGPTL2 and either fibrinogen or LAB in subgroups 
classified based on the duration of diabetes [group 1: 0-5 years (n =33), group 2: 
more than 5 to 10 years (n =16), group 3: more than 10-to 40 years (n =21)]. The 
number of patients treated with insulin was 12 (36%), 8 (50%), and 15 (71%), 
respectively in these groups. There was a significant correlation between 
ANGPTL2 and fibrinogen in group 1 (R =0.4493, P =0.0087) and in group 3 (R 
=0.6709, P =0.0017), but not in group 2 (R =0.3568, P =0.1749). ANGPTL2 was 
correlated with LAB only in group 3 (R =0.4507, P =0.0403), while no significant 
correlation was observed in group 1 (R =0.3347, P =0.0569) and in group 2 (R 
=0.1158, P =0.6695). There was a significant positive correlation between the 
duration of diabetes and the urinary albumin excretion (UAE)(R =0.4952, P 
<0.0001) and the CAVI index (R =0.3513, P =0.0038). 
 
Discussion 
In this study, serum ANGPTL2 levels were positively associated with hsCRP as an 
inflammatory marker, and these data are in agreement with previous studies.8,17 These 
results appear plausible given the fact that ANGPTL2 can cause inflammation in both 
adipose tissues and systemic vascular endothelial cells.2,3,8 However, this association was 
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lost in a multiple regression analysis except for 1 model in this study, which suggests that 
the association may be independent. On the other hand, ANGPTL2 was also positively 
correlated with fibrinogen, and the association was confirmed by multiple regression 
analysis. Therefore, the association between ANGPTL2 and fibrinogen is more 
dependent than that shown between ANGPTL2 and hsCRP. Although fibrinogen is an 
important factor associated with the coagulation system, it along with hsCRP are also 
representative inflammatory markers.29,30 We also previously reported the close positive 
correlation between these markers.31 Furthermore, a recent report suggests that baseline 
and long-term fibrinogen levels are associated with the risk of sudden cardiovascular 
death.32 Interestingly, it is reported that fibrinogen acts as a ligand for integrins (adhesion 
factors), including α5β1, which are abundantly expressed in monocytes, macrophages, 
and endothelial cells. Furthermore, this interaction promotes leukocyte adhesion and the 
secretion of cytokines resulting in inflammation. 29,30 On the other hand, it is likely that 
ANGPTL2 causes inflammation by activating the Ras-related C3 botulinus toxin 
substrate 1 (Rac1)/nuclear factor kappa-B (NFκB) pathway via α5β1 intergrin in vascular 
endothelial cells.8 This appears to be initiated by the binding of the C terminal fibrinogen-
like domain of ANGPTL2 to α5β1 intergrin. In contrast, ANGPTL2 is highly expressed 
in both vascular endothelial cells and infiltrated macrophages in atherosclerotic vessels 
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in humans, which may contribute to the elevation of ANGPTL2 in the circulation.9 Taken 
together, we speculate that circulating fibrinogen as well as circulating ANGPTL2 itself 
can also promote ANGPTL2 expression in vascular endothelial cells by a similar 
mechanism, resulting in the elevation of circulating ANGPTL2. It is possible that 
systemic vascular inflammation induced by ANGPTL2 contributes to the up-regulation 
of fibrinogen expression in the liver probably by cytokines produced in inflammatory 
cells, because it is reported that recombinant ANGPTL2 can promote the expression of 
pro-inflammatory cytokines, such as tumor necrosis factor α (TNFα) and interleukin 6 
(IL6).14 These mechanisms may partially explain the potentially close association 
between ANGPTL2 and fibrinogen found in this study. Another possible reason for this 
close association between ANGPTL2 and fibrinogen levels may be based on the issue of 
potential cross-reactivity of the antibodies in the ANGPTL2 kit used in this study with 
fibrinogen because ANGPTL2 has a C-terminal fibrinogen-like domain. However, both 
antibodies used in the sandwich ELISA have epitopes located in the coiled domain. On 
the other hand, the fibrinogen-like domain does not possess epitopes for these antibodies, 
and therefore these antibodies do not react with the fibrinogen-like domain in the 
ANGPTL family. Thus, it is unlikely that the antibodies used in this kit can cross-react 
with fibrinogen. 
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In this study, we found for the first time a significant positive association between 
serum ANGPLTL2 levels and serum LAB levels which reflects oxidized and modified 
LDL.21 The association was also confirmed by multiple regression analysis. Although it 
is evident that LDL-C is an important risk factor for cardiovascular events in type 2 
diabetic patients,18 the role of oxidized and modified LDL for the formation of atheroma 
was recently confirmed.19 Oxidized and modified LDL, but not LDL, can bind to LOX-
1 in vascular endothelial cells20 and cause local inflammation and a consequent 
atheroma.19 In fact, circulating LAB was positively associated with the CAVI-index (a 
marker of arterial stiffness) in men.33 Furthermore, it is reported that circulating LAB, 
but not sLOX-1, was associated with the risk of cardiovascular disease and ischemic 
stroke.34 The reason for the potential positive association between ANGPTL2 and LAB 
confirmed in this study is not fully apparent. However, the LAB levels are associated 
with lipid sedimentation,35 inflammation,36 and foam cell formation.37 Therefore, we 
speculate that LAB by this mechanism may be able to promote the expression of 
ANGPTL2 although this has not been directly demonstrated to date. Furthermore, 
because ANGPTL2 can induce oxidative stress,10 circulating ANGPTL2 or that 
expressed in endothelial cells appears to be partially involved in the oxidization of LDL. 
Based on these hypotheses for the mechanisms involved, it might be important to 
evaluate whether the possible association between ANGPTL2 and oxidized and 
modified LDL as reflected by the LAB levels can be a risk factor for cardiovascular 
disease in future studies with a larger number of patients. 
Interestingly, the correlation between ANGPTL2 and either fibrinogen or LAB 
was stronger in the subgroup with the longest duration of diabetes, compared with 
those in shorter duration of diabetes subgroups. As the progression of diabetes, 
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diabetic patients may have different complications and may use different 
medications which probably affect the levels of biomarkers. In fact, diabetic 
duration was positively correlated with the UAE and the CAVI-index, which 
generally respectively reflects diabetic nephropathy, and the degrees of 
arteriosclerosis, and the number of patients on insulin therapy was the highest in 
the subgroup with the longest duration of diabetes. This may have partially 
influenced the results.   
In this study, there was the negative correlation between ANGPTL2 levels and the 
eGFR. In addition, the trend toward a positive correlation between ANGPTL2 and the 
UAE was also noted. These findings, which support the results in a previous study,38 
suggest the close association between ANGPTL2 and the progression of diabetic 
nephropathy. One of the possible reasons for these results is likely due to the possible 
decrease of clearance in the kidney of ANGPTL2. However, the expression of 
ANGPTL2 in glomeruli in diabetic patients is up-regulated.39 In addition, ANGPTL2 
may promote fibrosis in the kidney due to the increased TGF via α5β1 
intergrin/extracellular signal-regulated kinase.40 Therefore, the association between 
ANGPTL2 and renal dysfunction observed in this study may be partially independent of 
the clearance of ANGPTL2 in the kidney. 
In the current study, the ANGPTL2 levels had a significant positive association 
with HbA1c in a multiple regression model with eGFR and HbA1c as independent 
variables. However, because the ANGPTL2 levels did not have a significant 
association with the HbA1c levels in both the correlation analysis and other models 
of multiple regression analyses, it does not appear that the ANGPLT2 levels were 
strongly influenced by the HbA1c levels. The result was basically in agreement with 
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previous reports16,38 although one study showed a significant positive association 
between ANGPTL2 and HbA1c levels.17 On the other hand, ANGPTL2 levels positively 
correlated with HOMA-IR, which reflects insulin resistance, in patients who did not 
receive insulin therapy. The result agrees with those in previous reports,8,17 and it 
appears to be a reasonable finding because ANGPTL2 is produced mainly in visceral 
adipose tissues and can cause inflammation, resulting in systemic increased insulin 
resistance.8  
In the current study, ANGPTL2 levels in type 2 diabetic patients were significantly 
higher compared with those in non-diabetic control subjects in agreement with a 
previous report.8 It is difficult to explain the detailed reason for this result because 
ANGPTL2 did not basically have a significant association with glycemic control, 
BMI, and age. In addition, there were no differences between BMI, age, and eGFR 
between these groups. Plausible explanations might include the potential difference in 
insulin resistance and low-grade inflammation between these groups. However, we did 
not measure serum insulin levels and inflammatory markers in the healthy subjects. 
There are some limitations of this study. This study was a cross-sectional 
observation. The number of diabetic patients was relatively small. This may have 
been especially important in the correlation between ANGPTL2 and either eGFR 
or LAB because the correlation coefficients were relatively small although these 
were statistically significant. Furthermore, the number of control subjects was 
very small compared with that of the diabetic patients, and this prevented us 
from investigating the correlation between ANGPTL2 and various markers in 
control subjects, resulting in the difficulty of comparing the difference in these 
correlations between diabetic patients and control subjects. In addition, the patients 
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took multiple different drugs for diabetes, which may have potentially influenced the 
circulating ANGPTL2 levels. Finally, cardiovascular events were not studied in this 
study so it could not be concluded that ANGPTL2 is a risk factor. 
In conclusion, ANGPTL2 levels in type 2 diabetic patients were significantly 
higher compared with those in non-diabetic control subjects. ANGPTL2 had a 
significant positive association with inflammatory markers evaluated by hsCRP, 
fibrinogen, and LAB, which reflects oxidized and modified LDL. There was a 
significant negative association between the serum ANGPTL2 levels and eGFR. On 
the other hand, ANGPTL2 were not basically influenced by glycemic control based on 
HbA1c or FPG, and by BMI. It is important that the potentially close association 
between ANGPTL2 and either LAB or fibrinogen be evaluated in a more detailed 
analysis for its clinical significance. 
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Figure Legends 
Fig. 1: 
Serum levels of ANGPTL2 in non-diabetic healthy subjects (n =9) and in type 2 
diabetic patients (n =70) 
Fig. 2 
The correlation between ANGPTL2 and either hsCRP (A), fibrinogen (B), LAB (C), 
and eGFR (D) in patients with type 2 diabetes 
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